Trial Profile
A Phase Ib/II Study of Palbociclib in Combination With Bazedoxifene in Hormone Receptor Positive Breast Cancer
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 25 Oct 2022
Price :
$35
*
At a glance
- Drugs Palbociclib (Primary) ; Bazedoxifene
- Indications Advanced breast cancer; Early breast cancer; HER2 negative breast cancer
- Focus Adverse reactions; Therapeutic Use
- 10 Oct 2022 Primary endpoint (Clinical Benefit Rate) has been met according to results published in the Clinical Cancer Research
- 10 Oct 2022 Results published in the Clinical Cancer Research
- 27 Jun 2022 Status changed from active, no longer recruiting to completed.